Clinical Trials Directory

Trials / Completed

CompletedNCT01203436

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
649 (actual)
Sponsor
NICHD Neonatal Research Network · Network
Sex
All
Age
48 Hours
Healthy volunteers
Not accepted

Summary

The purpose of this trial was to determine the efficacy and safety of supplemental therapeutic oxygen for infants with prethreshold retinopathy of prematurity (ROP) to reduce the probability of progression to threshold ROP and the need for peripheral retinal ablation.

Detailed description

Retinopathy of prematurity (ROP) is an abnormal growth of the blood vessels in the eye that occurs primarily in very premature infants. Eye development occurs normally in the womb; in infants born prematurely, however, the blood vessels must finish developing outside the protective environment of the uterus. Retinopathy of prematurity (also known as retrolental fibroplasia) is a leading cause of blindness and other vision impairments (myopia, strabismus, and amblyopia) in children, both in developed and developing countries. This study was a randomized trial comparing the effects of 2 oxygenation strategies on the progression of ROP. Infants with prethreshold ROP in at least one eye were eligible for the study. Enrolled infants were randomized to receive either conventional oxygenation at a pulse oximetry target of 89% to 94%, or supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%. Infant were placed on continuous pulse oximetry monitoring and to maintain oxygen saturation, as much as possible, in the assigned target range.

Conditions

Interventions

TypeNameDescription
PROCEDURESupplemental Oxygen ManagementSupplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
PROCEDUREConventional Oxygen ManagementConventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.

Timeline

Start date
1994-02-01
Primary completion
1999-03-01
Completion
1999-03-01
First posted
2010-09-16
Last updated
2015-06-08

Locations

9 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01203436. Inclusion in this directory is not an endorsement.